Castle Biosciences

OverviewSuggest Edit

Our first test for uveal melanoma, a rare and deadly eye cancer, is used to identify those at high risk for metastasis. With demonstrated improved accuracy over existing staging and prognostic tools, the test has become the standard of care for uveal melanoma and has successfully secured reimbursement. We are using its innovation as a model for our growing lineup of practice-changing tests, including our newer cutaneous (skin) melanoma prognostic assay. We have active development programs for assays in several other underserved cancers.
Castle Biosciences’ tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.

TypePublic
Founded2008
HQFriendswood, USMap
Websitecastlebiosciences.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2019)91(+2%)
Revenue (FY, 2018)$22.8 M(+66%)

Key People/Management at Castle Biosciences

Derek Maetzold

Derek Maetzold

Founder, President, and CEO
Bernhard E. Spiess

Bernhard E. Spiess

COO
Federico Monzon

Federico Monzon

Chief Medical Officer
Frank Stokes

Frank Stokes

CFO
Toby Juvenal

Toby Juvenal

Senior Vice President, Sales
Kristen Oelschlager

Kristen Oelschlager

Senior Vice President, Operations
Show more

Castle Biosciences Office Locations

Castle Biosciences has offices in Friendswood and Phoenix
Friendswood, US (HQ)
S Friendswood Dr
Phoenix, US
3737 N 7th St #160
Show all (2)

Castle Biosciences Financials and Metrics

Castle Biosciences Revenue

Embed Graph
View revenue for all periods
Castle Biosciences's revenue was reported to be $22.79 m in FY, 2018 which is a 65.7% increase from the previous period.
USD

Revenue (Q1, 2019)

8.7m

Gross profit (Q1, 2019)

7.1m

Gross profit margin (Q1, 2019), %

81.7%

Net income (Q1, 2019)

(1.4m)

EBIT (Q1, 2019)

(321.4k)

Cash (31-Mar-2019)

16.2m
Annual
USDFY, 2017FY, 2018

Revenue

13.8m22.8m

Revenue growth, %

66%

Cost of goods sold

4.9m5.3m

Gross profit

8.8m17.5m
Quarterly
USDQ1, 2018Q1, 2019

Revenue

3.7m8.7m

Cost of goods sold

1.3m1.6m

Gross profit

2.4m7.1m

Gross profit Margin, %

66%82%
show all
Annual
USDFY, 2017FY, 2018

Cash

1.2m4.5m

Accounts Receivable

4.7m12.1m

Prepaid Expenses

515.5k675.6k

Inventories

304.6k882.2k
Quarterly
USDQ1, 2019

Cash

16.2m

Accounts Receivable

9.2m

Prepaid Expenses

741.4k

Inventories

809.3k
show all
Annual
USDFY, 2017FY, 2018

Net Income

(12.4m)(6.4m)

Depreciation and Amortization

270.3k287.1k

Inventories

(115.6k)(577.7k)

Accounts Payable

370.9k197.2k
Quarterly
USDQ1, 2019Q1, 2020

Net Income

(3.6m)(1.4m)

Depreciation and Amortization

70.4k77.4k

Inventories

97.0k97.0k

Accounts Payable

(217.2k)(328.8k)
show all
USDY, 2019

EV/EBIT

-1.2 k x

EV/CFO

302.2 x

Revenue/Employee

112.2k

Financial Leverage

-10.7 x
Show all financial metrics

Castle Biosciences Operating Metrics

Q1, 2019

Clinical Samples Processed to Date

40 k
Show all operating metrics

Castle Biosciences Online and Social Media Presence

Castle Biosciences's Trends

Embed Graph

Castle Biosciences News and Updates

July 25, 2019

VC-backed Castle Biosciences goes public

Friendswood, Texas-based Castle Biosciences Inc, a dermatological cancer company, has raised $64 million for its IPO after pricing its 4 million shares at $16 per share. The stock began trading July 25, 2019 on the NASDAQ under the ticker symbol "CSTL." SVB Leerink and Baird are the lead underwriter…

Castle Biosciences Blogs

May 07, 2019

Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting

Friendswood, TX – May 7, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced two presentations at the 2019 American College of Mohs Surgery (ACMS) Annual Meeting held in Baltimore from M…
April 24, 2019

Castle Biosciences Receives 2019 Technology Innovation in Melanoma Award from American Skin Association

Friendswood, TX – April 24, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced that it has received the 2019 Technology Innovation in Melanoma Award from the American Skin Association (…
April 18, 2019

AMERICAN CANCER SOCIETY’S NEWLY FORMED PHILANTHROPIC IMPACT FUND MAKES FIRST INVESTMENT

ATLANTA, GA and FRIENDSWOOD, TX – April 18, 2019 – Castle Biosciences, Inc. and American Cancer Society’s newly formed philanthropic fund, BrightEdge, today announced that BrightEdge participated in a recent convertible note financing of Castle Biosciences of approximately $12 million. The investmen…
April 11, 2019

Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma

Friendswood, TX – April 11, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of 159 patients with cutaneous melanoma showing that the …
March 25, 2019

Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test

Friendswood, TX – March 25, 2019 – Castle Biosciences, Inc., a cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced that it will present five-year outcomes from a prospective, multicenter study showing that DecisionDx®-UM accur…
March 04, 2019

Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the 2019 AAD Annual Meeting

Friendswood, TX – March 4, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced three presentations at the 2019 American Academy of Dermatology (AAD) Annual Meeting held in Washington, DC…
Show more

 Castle Biosciences Frequently Asked Questions

  • When was Castle Biosciences founded?

    Castle Biosciences was founded in 2008.

  • Who are Castle Biosciences key executives?

    Castle Biosciences's key executives are Derek Maetzold, Bernhard E. Spiess and Federico Monzon.

  • How many employees does Castle Biosciences have?

    Castle Biosciences has 91 employees.

  • What is Castle Biosciences revenue?

    Latest Castle Biosciences annual revenue is $22.8 m.

  • What is Castle Biosciences revenue per employee?

    Latest Castle Biosciences revenue per employee is $250.4 k.

  • Who are Castle Biosciences competitors?

    Competitors of Castle Biosciences include Qvella, Universal Biosensors and Response Biomedical.

  • Where is Castle Biosciences headquarters?

    Castle Biosciences headquarters is located at S Friendswood Dr, Friendswood.

  • Where are Castle Biosciences offices?

    Castle Biosciences has offices in Friendswood and Phoenix.

  • How many offices does Castle Biosciences have?

    Castle Biosciences has 2 offices.